Results 101 to 110 of about 21,696 (215)

Refining the treatment of immune checkpoint inhibitor–associated myocarditis: Challenges, innovations and rechallenge considerations

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI)‐associated myocarditis has emerged as a severe and clinically complex immune‐related toxicity that poses significant challenges for therapeutic decision‐making in routine cardio‐oncological care. High‐dose corticosteroids remain the first‐line therapy, yet their timing, dosage and tapering require careful clinical ...
Raluca I. Mincu, Lisa Zimmer, Dimitra Vlachopoulou, Elias Haj‐Yehia, Julia Hoffmann, Lars Michel, Elisabeth Livingstone, Dirk Schadendorf, Alpaslan Tasdogan, Matthias Totzeck, Tienush Rassaf   +10 more
wiley   +1 more source

Structure of c-Src in complex with Ruxolitinib.

, 2014
(A) Overall structure of c-Src/Ruxolitinib complex. (B) The pyrrolopyrimidine rings form two hydrogen bonds with the main chain atoms of Met341. (C) Ruxolitinib forms a water-mediated interaction with Src gatekeeper residue Thr338.
Yongheng Chen (627094), Lin Chen (54305), Yankun Duan (627093), Xue-gong Fan (627095)   +3 more
core   +1 more source

Squamoid Eccrine Ductal Carcinoma: Case Series of a Rare, Potentially Aggressive Skin Cancer Associated With Immunosuppression

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Squamoid Eccrine Ductal Carcinoma (SEDC) is a rare cutaneous adenexal carcinoma first described in 1997. It has distinct biphasic features on histology which commonly result in misdiagnosis as Bowen disease or cutaneous squamous cell carcinomas (cSCC) if diagnostic skin biopsies are too superficial. This may lead to a delay in diagnosis. It is
Xiang Li Tan, Pooja Patel, Jeva Cernova, Sarah Hogan, Jason Thomson, Efthymios Hadjimichael, Sharanpal Jeetle, Dorota Markiewicz, Michael Sheaff, Nilukshi Wijesuriya, Mark Hawthorne, Graeme Moir, Matthew Stodell, Kapil Bhargava, Suchitra Chinthapalli, Catherine A. Harwood   +15 more
wiley   +1 more source

Elevated IL‐4 and IL‐13 Expression in Hailey‐Hailey Disease: Evidence for Th2‐Mediated Pathogenesis and Targeted Treatment

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Background Hailey‐Hailey disease (HHD) is a rare autosomal dominant blistering disorder caused by mutations in the ATP2C1 gene, which impair keratinocyte adhesion through disrupted calcium signaling. While traditionally considered a structural defect, recent studies suggest that Th2‐mediated inflammation may exacerbate disease pathology ...
Simonetta I. Gaumond, Victoria Soto, Beatriz Abdo Abujamra, Franco Rongioletti, John A. McGrath, Ivan Jozic, Paolo Romanelli   +6 more
wiley   +1 more source

Satisfaction with Control of Mild to Moderate Atopic Dermatitis with Ruxolitinib Cream: US Physician and Patient Perspectives

Dermatology and Therapy
Introduction The 2021 US approval of ruxolitinib cream for treatment of atopic dermatitis (AD) in patients aged ≥ 12 years was based on the results of two pivotal phase 3 studies.
Lawrence F. Eichenfield, Jinan Liu, Simran Marwaha, James Piercy, Daniel Sturm, Peter Anderson   +5 more
doaj   +1 more source

Out‐of‐pocket costs and time spent on disease management by vitiligo patients: a cross‐sectional questionnaire study in German‐speaking countries

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives The financial and time‐related burden of patients with vitiligo remains insufficiently studied. This study aimed to quantify out‐of‐pocket costs (OOPC) and time expenditure for vitiligo management and the associated sociodemographic, clinical, and behavioral factors in German‐speaking countries.
Christine Gasteiger, Michael Hindelang, Stefanie Ziehfreund, Hannah Wecker, Tilo Biedermann, Alexander Zink   +5 more
wiley   +1 more source

Venous Thromboembolism in Hematologic Malignancies: Incidence, Risk Factors, and the Role of Direct Oral Anticoagulants

European Journal of Haematology, EarlyView.
ABSTRACT Thrombotic events, particularly venous thromboembolism (VTE), are a significant source of morbidity and mortality among patients with hematologic malignancies. These patients face unique challenges due to treatment‐related complications such as thrombocytopenia, coagulopathy, and heightened bleeding risk.
Mario Biglietto, Silvia Sorella, Erminia Baldacci, Massimo Breccia, Sabina Chiaretti, Marcello Capriata, Livia Donzelli, Gianna Maria D'Elia, Salvatore Giacomo Morano, Ilaria Del Giudice, Maurizio Martelli, Cristina Santoro, Antonio Chistolini   +12 more
wiley   +1 more source

Ruxolitinib cream monotherapy demonstrates rapid improvement in the extent and signs of mild to moderate atopic dermatitis across head and neck and other anatomic regions in adolescents and adults: pooled results from 2 phase 3 studies

Journal of Dermatological Treatment
Purpose: Ruxolitinib (selective Janus kinase [JAK] 1 and JAK2 inhibitor) cream demonstrated efficacy and safety in patients with atopic dermatitis (AD) in the phase 3 TRuE-AD studies. In TRuE-AD1/TRuE-AD2 (NCT03745638/NCT03745651), adults and adolescents
Eric L. Simpson, Robert Bissonnette, Zelma C. Chiesa Fuxench, Howard Kallender, Daniel Sturm, Haobo Ren, Linda F. Stein Gold   +6 more
doaj   +1 more source

The role of ruxolitinib in the management of acute GVHD

Background and objectives: Following an allogeneic hematopoietic stem cell transplant (allo-HSCT), a primary cause of morbidity and mortality is still steroid-refractory acute graft-versus-host disease (SR-aGVHD). Recently, ruxolitinib, an oral inhibitor
Ulaş, Turgay, Altuntas, Fevzi, Ozet, Gulsum, Dal, Mehmet Sinan, Hidayet, Emine, NAMDAROĞLU, SİNEM, Cinar, Olgu Erkin, Korkmaz, Serdal, BERBER, İLHAMİ, Basturk, Abdulkadir, Yilmaz, Seda, Apaydin, Merve, ERKURT, MEHMET ALİ, Aydin, Muruvvet Seda   +13 more
core   +1 more source

Ruxolitinib-associated infections: A systematic review and meta-analysis

, 2017
Ruxolitinib exerts immunosuppressive activity that may increase the risk of infectious complications. We performed a systematic review of the literature with the aim of estimating the risk of infections in patients treated with ruxolitinib.
Marco Cattaneo, M.N. Cattaneo, A. Rambaldi, Alessandro Rambaldi, Lussana, Federico, Federico Lussana, CATTANEO, MARCO NATALE, Squizzato, Alessandro, Rambaldi, Alessandro, Alessandro Squizzato   +9 more
core   +1 more source